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Introduction to special edition, “State of the Field: Advances in
Neuroimaging from the 2016 Alzheimer’s Imaging Consortium”The Neuroimaging Professional Interest Area (NIPIA) of
the Alzheimer’s Association is honored to partner with
Alzheimer’s and Dementia: Diagnosis, Assessment and Dis-
ease Monitoring (DADM) on this inaugural special issue:
State of the Field: Advances in Neuroimaging from the
2016 Alzheimer’s Imaging Consortium. This special issue
comprises 12 original research and review articles from
the groups that were presented at the 2016 Alzheimer’s
Imaging Consortium (AIC) in Toronto, a one-day preconfer-
ence dedicated to advancements in the field of neuroimaging
in Alzheimer’s disease (AD) and related disorders.
The work within this special edition reflects the highly
relevant and timely topics emphasized at the 2016 AIC con-
ference—Tau Imaging, Imaging Genetics, and Brain Net-
works and Connectomics. The research presented at the
AIC conference and within this edition encapsulates
cutting-edge neuroimaging studies from research groups
across the globe. Data presented in the Tau Imaging session
were reflective of this rapidly evolving imaging modality
and spanned a diverse range of populations in which Tau pa-
thology may be particularly relevant—including compari-
sons of healthy younger and older normal control subjects
to typical AD dementia patients and rare microtubule-asso-
ciated protein tau (MAPT) mutation carriers. In the current
issue, Vemuri et al. in their study provide a thorough analysis
of regional Tau uptake measured using the AV1451 radio-
tracer in a large cohort of young and older participants [1].
Their analyses suggest that an age adjusted normalization
procedure can address signal properties that differ across
brain regions and facilitate regional comparisons. Shimada
et al. present a multimodality neuroimaging study of Tau
(11C-pyridinyl-butadienyl-benzothiazole 3 [PBB3]-Positron
emission tomography [PET]), Amyloid (11C-Pittsburgh
Compound B[PIB]-PET), and neuronal integrity [structural
magnetic resonance imaging [MRI] and 18F-Fludeoxyglu-
cose [FDG]-PET) in participants across the aging (young
and older normal control subjects) and AD spectrum [2].
These analyses revealed associations between medial tem-
poral lobe Tau and memory among low amyloid normals,
as well as the spreading of Tau beyond the medial temporal
lobe that was aligned with gray matter atrophy and hypome-http://dx.doi.org/10.1016/j.dadm.2016.12.008
2352-8729/ 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzhe
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).tabolism as the disease progressed. The work presented in
the Tau Imaging session and published herein are emblem-
atic of the role of this modality to glean insights into disease
progression, as well as to draw attention to important meth-
odological issues that will inform the interpretation of this
signal in human participants.
The Imaging Genetics session at AIC covered an array of
exciting findings and innovative analytical approaches,
providing excellent representation of the complex ap-
proaches that are necessary to link genetic data to imaging
phenotypes. This special edition features work by Stage
et al., who investigated individual a priori risk loci previ-
ously identified in the large International Genomics of
Alzheimer’s Disease Consortium Project genome-wide
association study (GWAS) contrasting AD patients with
control subjects [3]. Although multiple risk loci have
emerged from the International Genomics of Alzheimer’s
Disease Consortium Project analysis, mechanisms underly-
ing these genetic risk factors remain unknown and can be
informed using large neuroimaging studies. Stage analyses
revealed differential associations among individual risk var-
iants, brain atrophy, and glucose metabolism across the
disease spectrum. Work by Gispert et al. established the
impact of the APOE ε4 genotype on the association
between cerebrospinal fluid (CSF) markers of neuroinflam-
mation (YKL-40 and soluble TREM2) and brain atrophy
[4]. These analyses revealed, specifically in APOE ε41
carriers, that YKL-40 is elevated early in AD development
and that elevated YKL-40 was associated with worse tempo-
ral lobe atrophy. Thus, in addition to APOE ε4 being a risk
factor for abnormal accumulation of b-amyloid, this geno-
type may also exert a detrimental impact via inflammatory
pathways. Overall, the research presented at AIC and
covered within this edition on the topic of Imaging Genetics
provides important insight into the complexity of the herita-
bility of sporadic AD and the value of using imaging pheno-
types to elucidate underlying pathways.
The final topic featured at AIC was Brain Networks and
Connectomics. This session covers a wide array of topics,
demonstrating how measures of network integrity evolve
throughout the AD trajectory. Using an ICA approach,imer’s Association. This is an open access article under the CC BY-NC-ND
E.C. Mormino et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 5 (2016) 67-6968Contreras et al [5]. demonstrate that subjective cognitive
complaints and objective memory performance differen-
tially map onto connectivity changes across distinct brain
networks. Nuttall et al. in their study also examined integrity
across multiple brain networks, focusing on measures of
within and between-network connectivity [6]. This work
revealed that intranetwork connectivity was associated
with disease severity and that this effect was present across
multiple networks. Finally, Dickerson et al. provide an
alternative perspective on network involvement in AD by
implicating that multiple distinct spatial patterns of atrophy
exist among AD patients [7]. Specifically, this work revealed
that younger AD patients (age , 65 years) had atrophy in
brain networks involving the posterior cingulate, lateral
parietal, and frontal lobes, whereas older AD patients
(age . 80 years) demonstrated atrophy in brain networks
involving anterior medial and lateral temporal cortices.
Importantly, these patterns were largely nonoverlapping,
reflective of distinct networks defined by resting state func-
tional connectivity work, and consistent with a dissociation
in cognitive deficits across patient groups (the younger AD
dementia group was associated with an encoding deficit,
whereas the older AD dementia group demonstrated a se-
mantic memory deficit). Overall, this work spanning multi-
ple research groups and analytic approaches provides
important insight into the involvement of multiple brain net-
works in the AD trajectory.
In addition to the featured research topics covered at the
AIC conference, this special edition also includes work that
highlights the immediate clinical relevance of AD neuroi-
maging technologies. Vemuri et al. review the literature
surrounding imaging markers of cerebrovascular disease, a
topic that is relevant for understanding the impact of cere-
brovascular disease on dementia risk [9]. Work by Verfaillie
et al. [8] and Rana et al. [10] shows that baseline measures of
gray matter atrophy predict progression to AD dementia
among clinically asymptomatic participants. Along these
lines, La Joie et al. in their study examined the associations
between item-specific cognitive complaints and abnormal
amyloid levels among nondemented older individuals and
found that a specific profile of complaints may be predictive
of early amyloid accumulation [11]. The ability to predict
future progression and the presence of elevated abnormal
amyloid among asymptomatic older individuals is of utmost
importance as the field moves toward prevention strategies
and aims to identify at risk individuals before clinical symp-
toms are present. Finally, Apostolova et al. in their study
explore the “Appropriate Use Criteria” for Amyloid Imaging
in AD dementia patients scanned with Florbetapir PET [12].
This study found that early onset patients were more likely to
be amyloid positive and were more likely to undergo a
change in therapy based on amyloid scan results, high-
lighting the utility of amyloid PET imaging in the manage-
ment of patients with early onset AD. Furthermore, the
higher rate of amyloid-negative scans in the late onset group,despite this group being inconsistent with the Appropriate
Use Criteria, suggests a utility of amyloid PET in this popu-
lation as well.
Overall, the research comprising this special edition
reveal promising insights into the AD trajectory, and high-
light the ability to measure these processes in living humans
using neuroimaging.Elizabeth C. Morminoa,*
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